Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M.
PMID: 17440629
Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73.

Agomelatine, AGRO-100, AIDSVAX gp120 B/E, alfimeprase, aliskiren fumarate, ALVAC vCP1452, alvocidib hydrochloride, ambrisentan, AME-527, AN-0128, apadenoson, ARRY-142886, asenapine maleate, axitinib, azimilide hydrochloride; Belimumab, bevacizumab, biolimus A9, BiovaxID, bryostatin 1; Cannabidiol, celgosivir, CG-1940/CG-8711, CKD-501, collagen-PVP, CpG-10101, CTL-102, CTL-102/CB-1954; D-4F, darusentan,...

Cite
Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29(2):153-73
Bayes, M. (2007). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 29(2), 153-73.
Bayes, Miriam. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 29,2 (2007): 153-73.
Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73. PMID: 17440629.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 19557204
Methods Find Exp Clin Pharmacol. 2009 May;31(4):263-98. doi: 10.1358/mf.2009.31.4.1373959.

(-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG-317, Amlodipine, Aripiprazole, Atazanavir sulfate, Azacitidine; Becatecarin, Belinostat, Bevacizumab, BMS-387032, BMS-690514, Bortezomib; Casopitant mesylate, Cetuximab, Choline fenofibrate, CK-1827452, Clofarabine, Conivaptan hydrochloride; Dabigatran etexilate, DADMe-Immucillin-H, Darbepoetin alfa, Darunavir, Dasatinib, DC-WT1,...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009;31(4):263-98doi: 10.1358/mf.2009.31.4.1373959.
Tomillero, A., & Moral, M. A. (2009). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 31(4), 263-98. https://doi.org/10.1358/mf.2009.31.4.1373959
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 31,4 (2009): 263-98. doi: https://doi.org/10.1358/mf.2009.31.4.1373959
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 May;31(4):263-98. doi: 10.1358/mf.2009.31.4.1373959. PMID: 19557204.
Copy Download .nbib Format: NLM
Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis.

PeerJ

Hao M, Liu W, Ding C, Peng X, Zhang Y, Chen H, Dong L, Liu X, Zhao Y, Chen X, Khatoon S, Zheng Y.
PMID: 33083112
PeerJ. 2020 Sep 29;8:e9946. doi: 10.7717/peerj.9946. eCollection 2020.

Breast cancer is one of the most common malignant tumors among women worldwide and has a high morbidity and mortality. This research aimed to identify hub genes and small molecule drugs for breast cancer by integrated bioinformatics analysis. After...

Cite
Hao M, Liu W, Ding C, et al. Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis. PeerJ. 2020;8:e9946doi: 10.7717/peerj.9946.
Hao, M., Liu, W., Ding, C., Peng, X., Zhang, Y., Chen, H., Dong, L., Liu, X., Zhao, Y., Chen, X., Khatoon, S., & Zheng, Y. (2020). Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis. PeerJ, 8e9946. https://doi.org/10.7717/peerj.9946
Hao, Mingqian, et al. "Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis." PeerJ vol. 8 (2020): e9946. doi: https://doi.org/10.7717/peerj.9946
Hao M, Liu W, Ding C, Peng X, Zhang Y, Chen H, Dong L, Liu X, Zhao Y, Chen X, Khatoon S, Zheng Y. Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis. PeerJ. 2020 Sep 29;8:e9946. doi: 10.7717/peerj.9946. eCollection 2020. PMID: 33083112; PMCID: PMC7556247.
Copy Download .nbib Format: NLM
Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma.

Journal of clinical haematology

Zhang XH, Hsiang J, Rosen ST.
PMID: 34223559
J Clin Haematol. 2021;2(2):48-61. doi: 10.33696/haematology.2.028. Epub 2021 May 04.

Flavopiridol (FVP; Alvocidib), a CDKs inhibitor, is currently undergoing clinical trials for treatment of leukemia and other blood cancers. Our studies demonstrated that FVP also inhibited p38 kinases activities with IC

Cite
Zhang XH, Hsiang J, Rosen ST. Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma. J Clin Haematol. 2021;2(2):48-61doi: 10.33696/haematology.2.028.
Zhang, X. H., Hsiang, J., & Rosen, S. T. (2021). Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma. Journal of clinical haematology, 2(2), 48-61. https://doi.org/10.33696/haematology.2.028
Zhang, Xu Hannah, et al. "Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma." Journal of clinical haematology vol. 2,2 (2021): 48-61. doi: https://doi.org/10.33696/haematology.2.028
Zhang XH, Hsiang J, Rosen ST. Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma. J Clin Haematol. 2021;2(2):48-61. doi: 10.33696/haematology.2.028. Epub 2021 May 04. PMID: 34223559; PMCID: PMC8248901.
Copy Download .nbib Format: NLM
Combined venetoclax and alvocidib in acute myeloid leukemia.

Oncotarget

Bogenberger J, Whatcott C, Hansen N, Delman D, Shi CX, Kim W, Haws H, Soh K, Lee YS, Peterson P, Siddiqui-Jain A, Weitman S, Stewart K, Bearss D, Mesa R, Warner S, Tibes R.
PMID: 29291023
Oncotarget. 2017 Nov 03;8(63):107206-107222. doi: 10.18632/oncotarget.22284. eCollection 2017 Dec 05.

More effective treatment options for elderly acute myeloid leukemia (AML) patients are needed as only 25-50% of patients respond to standard-of-care therapies, response duration is typically short, and disease progression is inevitable even with some novel therapies and ongoing...

Cite
Bogenberger J, Whatcott C, Hansen N, et al. Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget. 2017;8(63):107206-107222doi: 10.18632/oncotarget.22284.
Bogenberger, J., Whatcott, C., Hansen, N., Delman, D., Shi, C. X., Kim, W., Haws, H., Soh, K., Lee, Y. S., Peterson, P., Siddiqui-Jain, A., Weitman, S., Stewart, K., Bearss, D., Mesa, R., Warner, S., & Tibes, R. (2017). Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget, 8(63), 107206-107222. https://doi.org/10.18632/oncotarget.22284
Bogenberger, James, et al. "Combined venetoclax and alvocidib in acute myeloid leukemia." Oncotarget vol. 8,63 (2017): 107206-107222. doi: https://doi.org/10.18632/oncotarget.22284
Bogenberger J, Whatcott C, Hansen N, Delman D, Shi CX, Kim W, Haws H, Soh K, Lee YS, Peterson P, Siddiqui-Jain A, Weitman S, Stewart K, Bearss D, Mesa R, Warner S, Tibes R. Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget. 2017 Nov 03;8(63):107206-107222. doi: 10.18632/oncotarget.22284. eCollection 2017 Dec 05. PMID: 29291023; PMCID: PMC5739808.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 20664824
Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420.

[¹¹C]RAC; (18)F-Fluoromisonidazole; 89-12; 9-[¹⁸F]Fluoropropyl-(+)-dihydrotetrabenazine; Adalimumab, Adecatumumab, ADMVA, ADXS-11-001, Aflibercept, Agatolimod sodium, AGS-004, Alglucosidase alfa, Aliskiren fumarate, Alvocidib hydrochloride, AMG-108, AMG-853, Apixaban, Aripiprazole, Armodafinil, Atazanavir sulfate, Atomoxetine hydrochloride; Bevacizumab, BioMatrix Flex drug eluting stent, Biphasic insulin aspart, Bortezomib, Bosentan; Caspofungin...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010;32(5):331-88doi: 10.1358/mf.2010.32.5.1520420.
Tomillero, A., & Moral, M. A. (2010). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 32(5), 331-88. https://doi.org/10.1358/mf.2010.32.5.1520420
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 32,5 (2010): 331-88. doi: https://doi.org/10.1358/mf.2010.32.5.1520420
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420. PMID: 20664824.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18597009
Methods Find Exp Clin Pharmacol. 2008 Apr;30(3):231-51.

(-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC-1779; Belimumab, BIBW-2992, Binodenoson, Bortezomib, Bosutinib, Brivaracetam; Cediranib, Clevidipine, CNTO-328, CP-751871, Curcumin; Darapladib, Deforolimus, Denosumab, Desvenlafaxine succinate, Dipyridamole/prednisolone, Dronedarone hydrochloride, DTPw-HBV/Hib 2.5; Ecogramostim, Elacytarabine, Eltrombopag, Eprodisate sodium; Farnesylthiosalicylic acid,...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(3):231-51
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 30(3), 231-51.
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 30,3 (2008): 231-51.
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Apr;30(3):231-51. PMID: 18597009.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 17344945
Methods Find Exp Clin Pharmacol. 2007 Jan-Feb;29(1):53-71.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29(1):53-71
Bayés, M., Rabasseda, X., & Prous, J. R. (2007). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 29(1), 53-71.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 29,1 (2007): 53-71.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jan-Feb;29(1):53-71. PMID: 17344945.
Copy Download .nbib Format: NLM
The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.

Oncotarget

Zocchi L, Wu SC, Wu J, Hayama KL, Benavente CA.
PMID: 29805751
Oncotarget. 2018 May 04;9(34):23505-23518. doi: 10.18632/oncotarget.25239. eCollection 2018 May 04.

Osteosarcoma is the most common primary malignant neoplasm of bone and typically occurs in children and young adults. As a highly metastatic malignancy, 15-20% of osteosarcoma patients are diagnosed after the tumor has already metastasized (typically to the lungs),...

Cite
Zocchi L, Wu SC, Wu J, et al. The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells. Oncotarget. 2018;9(34):23505-23518doi: 10.18632/oncotarget.25239.
Zocchi, L., Wu, S. C., Wu, J., Hayama, K. L., & Benavente, C. A. (2018). The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells. Oncotarget, 9(34), 23505-23518. https://doi.org/10.18632/oncotarget.25239
Zocchi, Loredana, et al. "The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells." Oncotarget vol. 9,34 (2018): 23505-23518. doi: https://doi.org/10.18632/oncotarget.25239
Zocchi L, Wu SC, Wu J, Hayama KL, Benavente CA. The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells. Oncotarget. 2018 May 04;9(34):23505-23518. doi: 10.18632/oncotarget.25239. eCollection 2018 May 04. PMID: 29805751; PMCID: PMC5955096.
Copy Download .nbib Format: NLM
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.

Blood cancer journal

Zeidner JF, Lin TL, Vigil CE, Fine G, Yair Levy M, Nazha A, Esteve J, Lee DJ, Yee K, Dalovisio A, Wang ES, Bergua Burgues JM, Schriber J, Litzow MR, Frankfurt O, Castillo TBD, Bhatt VR, Bhatnagar B, Mehta P, Dillon R, Vicente MV, Anthony S, Bearss D, Montesinos P, Douglas Smith B.
PMID: 34718324
Blood Cancer J. 2021 Oct 30;11(10):175. doi: 10.1038/s41408-021-00568-3.

No abstract available.

Cite
Zeidner JF, Lin TL, Vigil CE, et al. A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. Blood Cancer J. 2021;11(10):175doi: 10.1038/s41408-021-00568-3.
Zeidner, J. F., Lin, T. L., Vigil, C. E., Fine, G., Yair Levy, M., Nazha, A., Esteve, J., Lee, D. J., Yee, K., Dalovisio, A., Wang, E. S., Bergua Burgues, J. M., Schriber, J., Litzow, M. R., Frankfurt, O., Castillo, T. B. D., Bhatt, V. R., Bhatnagar, B., Mehta, P., Dillon, R., Vicente, M. V., Anthony, S., Bearss, D., Montesinos, P., & Douglas Smith, B. (2021). A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. Blood cancer journal, 11(10), 175. https://doi.org/10.1038/s41408-021-00568-3
Zeidner, Joshua F, et al. "A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia." Blood cancer journal vol. 11,10 (2021): 175. doi: https://doi.org/10.1038/s41408-021-00568-3
Zeidner JF, Lin TL, Vigil CE, Fine G, Yair Levy M, Nazha A, Esteve J, Lee DJ, Yee K, Dalovisio A, Wang ES, Bergua Burgues JM, Schriber J, Litzow MR, Frankfurt O, Castillo TBD, Bhatt VR, Bhatnagar B, Mehta P, Dillon R, Vicente MV, Anthony S, Bearss D, Montesinos P, Douglas Smith B. A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. Blood Cancer J. 2021 Oct 30;11(10):175. doi: 10.1038/s41408-021-00568-3. PMID: 34718324; PMCID: PMC8557202.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 17235418
Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006;28(10):719-40
Bayes, M., Rabasseda, X., & Prous, J. R. (2006). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 28(10), 719-40.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 28,10 (2006): 719-40.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40. PMID: 17235418.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18806898
Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408.

(+)-Dapoxetine hydrochloride, (R)-Etodolac; Abatacept, ABT-510, Adalimumab, Agatolimod sodium, Alemtuzumab, Alvocidib hydrochloride, Aminolevulinic acid methyl ester, Aripiprazole, AS01B, AS02B, AS02V, Azacitidine; Becatecarin, Bevacizumab, Bevirimat, Bortezomib, Bremelanotide; CAIV-T, Canfosfamide hydrochloride, CHR-2797, Ciclesonide, Clevidipine; Darbepoetin alfa, Decitabine, Degarelix acetate, Dendritic cell-based vaccine,...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(5):383-408
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 30(5), 383-408.
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 30,5 (2008): 383-408.
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408. PMID: 18806898.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries